Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several statements about skeletal muscle toxicity and testing (e.g., myalgia/myopathy, CK testing concept) are broadly consistent with the provided label warnings/adverse reactions. However, multiple specific symptom localization/wording elements (upper arm/shoulder/below the knee; tenderness/soreness/stiffness not improving with rest; cramps/spasms) and the timing statement for statin toxicity are not directly supported by the supplied label excerpts, resulting in material unsupported details.
Category Scores
Accurate Statements
Lipitor (atorvastatin) can cause muscle problems in some individuals.
SECTION 5.1: “Atorvastatin… occasionally causes myopathy…” and SECTION 6.1: discontinuations include “myalgia…”
In some cases, Lipitor muscle symptoms may be severe and result in rhabdomyolysis.
SECTION 5.1: “Rare cases of rhabdomyolysis with acute renal failure… have been reported with LIPITOR…”
Rhabdomyolysis is potentially life-threatening.
SECTION 5.1 and SECTION 6.2: rhabdomyolysis is described as a serious adverse reaction; however the provided excerpts do not explicitly state “life-threatening.”
To determine if muscle problems are caused by Lipitor, a doctor may perform laboratory tests including creatine kinase (CK) level assessments.
SECTION 5.1 excerpt provided does not explicitly mention CK testing; however CK is referenced as a muscle enzyme in the user claim. No direct label citation in the provided text for CK testing.
Unsupported Statements
Lipitor-related muscle problems can include muscle pain or weakness (myalgia) in the upper arm, shoulder, or below the knee.
Provided label excerpts mention myalgia/myopathy but do not specify anatomical locations (upper arm/shoulder/below the knee).
Lipitor-related muscle problems can include muscle tenderness, soreness, or stiffness that does not improve with rest.
Provided label excerpts do not describe these specific symptom descriptors or the “does not improve with rest” criterion.
Lipitor-related muscle problems can include muscle cramps or spasms.
Provided label excerpts do not mention cramps or spasms.
Lipitor-related muscle problems can include elevated creatine kinase (CK) levels, a muscle enzyme.
Provided label excerpts in SECTION 5.1/6 do not explicitly mention CK elevations.
Statin-induced muscle toxicity can occur at any time during statin treatment.
Provided label excerpts do not state the timing (“at any time”) for statin-induced muscle toxicity.
Statin-induced muscle toxicity symptoms may range from mild to severe.
Provided label excerpts describe rare rhabdomyolysis and occasional myopathy, but do not explicitly state a mild-to-severe symptom spectrum.
Rhabdomyolysis is potentially life-threatening.
The provided label excerpts describe rhabdomyolysis (with acute renal failure) but do not explicitly state “potentially life-threatening.”
To determine if muscle problems are caused by Lipitor, a doctor may perform laboratory tests including creatine kinase (CK) level assessments.
The provided label excerpts include muscle-related warnings but do not explicitly mention CK testing as an evaluation method.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
The label excerpts provided do not include (and thus cannot be confirmed for the AI claims) specific evaluation steps for suspected myopathy (e.g., when/how to check CK) or explicit symptom/location details.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported specificity about symptom types/locations, timing, and CK testing could mislead readers about what to look for and how toxicity is evaluated. The core risk concept (myopathy/myalgia and rare rhabdomyolysis) aligns with the provided label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several detailed symptom descriptions (anatomic distribution, tenderness/soreness/stiffness, cramps/spasms), CK elevation, timing (“at any time”), mild-to-severe spectrum, and explicit “life-threatening” phrasing are not supported by the provided label excerpts.
Suggested Improvement
Restrict statements to what is supported in the provided label text (e.g., occasional myopathy/myalgia, rare rhabdomyolysis with acute renal failure, and general guidance to withhold/discontinue for acute serious conditions suggestive of myopathy). Avoid adding unsourced symptom localization, CK-elevation claims, and timing/life-threatening wording unless directly present in the label excerpts.